Главная
Study mode:
on
1
Introduction
2
How did we get here
3
Why is this happening
4
How can we tackle this
5
Betalactamase inhibitors
6
Potential for antagonism
7
AMR Action Fund
8
Thoughts on AMR Fund
9
Solutions
10
Predictions
11
FDA vs clinical trials
12
Lack of patients
13
Regulatory environment
14
Nonprofit
15
Small pipeline
16
Antibiotic incentives
17
Final thoughts
Description:
Explore the critical issue of antibiotic scarcity in this 44-minute conversation featuring experts Dr. Helen Boucher and Dr. Karen Bush. Delve into the reasons behind the declining antibiotic development pipeline, examine new initiatives aimed at revitalizing the antibiotic market, and discover strategies to boost antibiotic development. Learn about the challenges facing pharmaceutical companies, the potential of betalactamase inhibitors, and the impact of regulatory environments on drug development. Gain insights into the AMR Action Fund, nonprofit approaches, and proposed incentives to stimulate antibiotic research. Understand the complexities of clinical trials, patient recruitment issues, and the evolving landscape of antimicrobial resistance. Conclude with expert predictions and final thoughts on addressing this global health concern.

The Dearth of Antibiotic Development

American Society for Microbiology
Add to list
0:00 / 0:00